RxDoctor Payments Data

Carolyn Williams

Family · Louisville, KYNPI 1881047769

Payments from drug & device makers

$2,509in general payments, 2019–2025

Across 92 payments — averaging $27.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sumitomo Pharma America, Inc.$461
  • Coloplast$276
  • Astellas Pharma US Inc$163
  • Hollister Incorporated$161
  • Rochester Medical Corporation$144
  • Procept Biorobotics Corporation$141
  • plus $1K from 23 others

What the payments were for

  • Food & beverage$2,41096%
  • Education$994%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,509 in reported general payments places this provider in the 80th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$42,495
Medicare patients
250
Services billed
858

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron188$133,233
MyrbetriqMirabegron100$66,566
Mirabegron ErMirabegron16$13,230
Tamsulosin Hcl357$3,015
Finasteride273$2,419
Estradiol24$2,109
Trospium Chloride ErTrospium Chloride11$1,051
Oxybutynin Chloride ErOxybutynin Chloride31$884
Testosterone Cypionate32$811
NitrofurantoinNitrofurantoin Macrocrystal22$657
Tadalafil16$657
Betamethasone Dipropionate14$602
Alfuzosin Hcl ErAlfuzosin Hcl49$482
Oxybutynin Chloride17$443
Solifenacin Succinate17$420

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$461$133,233188 claims
Astellas Pharma US IncMyrbetriq$163$66,566100 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,374 family providers in Kentucky.

Other family in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →